What is Volta Labs?
Volta Labs operates at the intersection of biology and automation, specializing in the development of sophisticated hardware and software solutions designed to streamline upstream workflows in genomic sequencing. By automating complex, manual laboratory processes, the company effectively reduces human error and increases the efficiency of high-throughput sequencing facilities. This market position is increasingly vital as the global demand for rapid, accurate genomic data continues to surge across clinical diagnostics, pharmaceutical research, and personalized medicine sectors. Volta Labs serves as a critical infrastructure provider, enabling laboratories to focus on data interpretation rather than the labor-intensive preparation of biological samples.
How much funding has Volta Labs raised?
Volta Labs has raised a total of $20M across 1 funding round:
Series A
$20M
Series A (2022): $20M with participation from Casdin Capital, Maverick Ventures, Khosla Ventures, E14 Fund, Blindspot Ventures, and John Steulpnagel
Key Investors in Volta Labs
Casdin Capital
Casdin Capital brings a deep understanding and long-term perspective to financing the next generation of life science innovation, with a specific focus on diagnostics and molecular information.
Khosla Ventures
Khosla Ventures provides strategic advice and capital to entrepreneurs working on breakthrough technologies across a broad range of sectors including health, AI, and enterprise infrastructure.
Maverick Ventures
Maverick Ventures is a venture capital firm dedicated to supporting technology start-ups by providing investment and operational support, with a focus on healthcare and differentiated technology.
What's next for Volta Labs?
With the successful closure of its latest funding round, Volta Labs is poised to enter a phase of aggressive commercial expansion and product iteration. The strategic roadmap likely includes the scaling of manufacturing capabilities to meet enterprise-level demand and the further refinement of its bioautomation suite to integrate with next-generation sequencing platforms. As the company matures, the focus will shift toward establishing deeper partnerships with major diagnostic laboratories and research institutions, effectively cementing its role as a foundational player in the genomic infrastructure ecosystem. Investors will be monitoring the company's ability to maintain its technological edge while navigating the complexities of global supply chains and the evolving regulatory environment for medical and research instrumentation.
See full Volta Labs company page
